Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease

Critical Care Medicine

Volumn 34, Issue 4, 2006, Pages 1044-1051

  Klarenbach, Scott W ^a,c   Pannu, Neesh ^a   Tonelli, Marcello A ^a,c   Manns, Braden J ^b,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

Author keywords

Contrast media; Costs and cost analysis; Decision support techniques; Hemofiltration; Kidney failure

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CREATININE; SODIUM CHLORIDE;

AGED; ANGIOGRAPHY; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH SERVICE; HEMOFILTRATION; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; TERTIARY HEALTH CARE;

AGED; CHRONIC DISEASE; CONTRAST MEDIA; COST-BENEFIT ANALYSIS; HEMOFILTRATION; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE;

EID: 33645838630     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000206287.22318.C3     Document Type: Article

References (51)

1. McCullough PA, Wolyn R, Rocher LL, et al: Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368-375
2. Gruberg L, Mehran R, Dangas G, et al: Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001; 52:409-416
3. Gruberg L, Mintz GS, Mehran R, et al: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36:1542-1548
4. Vogt B, Ferrari P, Schonholzer C, et al: Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111:692-698
5. Rihal CS, Textor SC, Grill DE, et al: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264
6. Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial: The lohexol Cooperative Study. Kidney Int 1995; 47:254-261
7. McCullough PA, Sandberg KR: Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003; 4(Suppl 5):S3-S9
8. Asif A, Epstein M: Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004; 44:12-24
9. Solomon R, Werner C, Mann D, et al: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416-1420
10. Abizaid AS, Clark CE, Mintz GS, et al: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999; 83:260-3, A5
11. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality: A cohort analysis. JAMA 1996; 275:1489-1494
12. Mehran R, Aymong ED, Nikolsky E, et al: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004; 44:1393-1399
13. Marenzi G, Marana I, Lauri G, et al: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349:1333-1340
14. Kancha K, Lee J, Ahmed Z: Hemofiltration and the prevention of radiocontrast-agent-induced nephropathy. N Engl J Med 2004; 350:836-838
15. Thomsen HS: How to avoid CIN: Guidelines from the European Society of Urogenital Radiology. Nephrol Dial Transplant 2005; 20:i18-i22
16. Gold MR, Siegel J, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
17. Drummond MF: Methods for the economic evaluation of health care programmes. Oxford and New York, Oxford University Press, 1997
18. Drummond MF, McGuire A: Economic Evaluation in Health Care: Merging Theory with Practice. Oxford and New York, Oxford University Press, 2001
19. Merten GJ, Burgess WP, Gray LV, et al: Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291:2328-2334
20. Maeder M, Klein M, Fehr T, et al: Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 2004; 44:1763-1771
21. Billinger M, Hess OM, Meier B: Prevention of contrast-induced renal dysfunction by N-acetylcysteine: Truth or myth? Eur Heart J 2004; 25:188-189
22. Birck R, Krzossok S, Markowetz F, et al: Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 2003; 362:598-603
23. Isenbarger DW, Kent SM, O'Malley PG: Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003; 92:1454-1458
24. Alonso A, Lau J, Jaber BL, et al: Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004; 43:1-9
25. Pannu N, Manns B, Lee H, et al: Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004; 65:1366-1374
26. Best PJ, Lennon R, Ting HH, et al: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39:1113-1119
27. Naidu SS, Selzer F, Jacobs A, et al: Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol 2003; 92:1160-1164
28. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89:356-358
29. U.S. Renal Data Systems. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Washington, DC, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002
30. Collins AJ, Li S, Gilbertson DT, et al: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003; 87:S24-S31
31. McClellan WM, Langston RD, Presley R: Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004; 15:1912-1919
32. Melsop KA, Boothroyd DB, Hlatky MA: Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J 2003; 145:36-41
33. Manns B, Johnson JA, Taub K, et al: Quality of life in patients treated with hemodialysis or peritoneal dialysis: What are the important determinants? Clin Nephrol 2003; 60:341-351
34. Tengs TO, Wallace A: One thousand health-related quality-of-life estimates. Med Care 2000; 38:583-637
35. Rubenstein MH, Sheynberg BV, Harrell LC, et al: Effectiveness of and adverse events after percutaneous coronary intervention in patients with mild versus severe renal failure. Am J Cardiol 2001; 87:856-860
36. Calvin JE, Klein L, VandenBerg E, et al: The intermediate CCU admission: A preliminary study. Heart Dis 2001; 3:18-23
37. Noseworthy TW, Konopad E, Shustack A, et al: Cost accounting of adult intensive care: Methods and human and capital inputs. Crit Care Med 1996; 24:1168-1172
38. Gaspoz JM, Lee TH, Weinstein MC, et al: Cost-effectiveness of a new short-stay unit to "rule out" acute myocardial infarction in low risk patients. J Am Coll Cardiol 1994; 24:1249-1259
39. Manns B, Doig CJ, Lee H, et al: Cost of acute renal failure requiring dialysis in the intensive care unit: Clinical and resource implications of renal recovery. Crit Care Med 2003; 31:449-455
40. Tretiak R, Laupacis A, Riviere M, et al: Cost of allogeneic and autologous blood transfusion in Canada: Canadian Cost of Transfusion Study Group. CMAJ 1996; 154:1501-1508
41. Jacobs P: A National List of Provincial Costs for Health Care: Canada 1997/8, 2000
42. Lee H, Manns B, Taub K, et al: Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002; 40:611-622
43. Green LV: How many hospital beds? Inquiry 2002; 39:400-412
44. Laupacis A, Feeny D, Detsky AS, et al: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-481
45. Ubel PA, Hirth RA, Chernew ME, et al: What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163:1637-1641
46. Kay J, Chow WH, Chan TM, et al: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA 2003; 289:553-558
47. Frank H, Werner D, Lorusso V, et al: Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 2003; 60:176-182
48. Matzkies FK, Reinecke H, Tombach B, et al: Influence of dialysis procedure, membrane surface and membrane material on iopromide elimination in patients with reduced kidney function. Am J Nephrol 2000; 20:300-304
49. Furukawa T, Ueda J, Takahashi S, et al: Elimination of low-osmolality contrast media by hemodialysis. Acta Radiol 1996; 37:966-971
50. Ueda J, Furukawa T, Higashino K, et al: Elimination of iomeprol by hemodialysis. Eur J Radiol 1996; 23:197-200
51. Waaler A, Svaland M, Fauchald P, et al: Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure. Nephron 1990; 56:81-85